PMV Pharmaceuticals, Inc (PMVP)

Etorro trading 970x250
PMV Pharmaceuticals, Inc (PMVP) Logo

About PMV Pharmaceuticals, Inc

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule, tumor-agnostic therapies for p53 mutations in cancer. The company’s lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores p53 function. It is also developing p53 R273H mutation and other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey. Address: 8 Clarke Drive, Cranbury, NJ, United States, 08512

PMV Pharmaceuticals, Inc News and around…

Latest news about PMV Pharmaceuticals, Inc (PMVP) common stock and company :

PMV Pharma to Present at the Evercore ISI 4th Annual HealthCONx Conference
22 Nov, 2021 Yahoo! Finance

CRANBURY, N.J., Nov. 22, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants, today announced that David H. Mack, Ph.D., President & Chief Executive Officer, will represent PMV Pharma in a “Fireside Chat” at the Evercore ISI 4th Annual HealthCONx Conference taking place November 30 – December 2, 2021. The company will also participate in one-on-on

PMV Pharmaceuticals Reports Third Quarter 2021 Financial Results and Corporate Highlights
12 Nov, 2021 Yahoo! Finance

CRANBURY, N.J., Nov. 12, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a clinical-stage oncology company pioneering the discovery and development of small molecule therapies designed to activate p53 function, today reported financial results for the third quarter ended September 30, 2021 and provided corporate highlights. “We made important progress in the third quarter of 2021 as we advanced the clinical development of our lead candidate, PC14586, an investigational small m

Analysts Predict 16% Gains Ahead For VBK
29 Oct, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Small-Cap Growth ETF (VBK), we found that the implied analyst target price for the ETF based upon its underlying holdings is $343.47 per unit.

RSI Alert: PMV Pharmaceuticals (PMVP) Now Oversold
13 Oct, 2021 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

Pmv Pharmaceuticals Insider Trades $440K In Company Stock
05 Oct, 2021 Yahoo! Finance

Thilo Schroeder, Director at Pmv Pharmaceuticals (NASDAQ:PMVP), made a large insider sell on October 4, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Monday showed that Schroeder sold 14,619 shares of Pmv Pharmaceuticals at prices ranging from $30.03 to $30.10. The total transaction amounted to $439,821. Schroeder still owns a total of 1,102,083 shares of Pmv Pharmaceuticals worth, $31,905,302. Pmv Pharmaceuticals shares are tra

Goldman Sachs: Buy These 2 Stocks Before They Jump 40% (or More)
28 Sep, 2021 Yahoo! Finance

Markets are up this year – that’s no news, the gains have been substantial and sustained – but recent weeks have made investors nervous. The resurgence of COVID, rising inflation and stubbornly high unemployment have already made headlines, but new problems are coming up overseas. In China, for example, a developing debt crisis in the giant Evergrande Group threatens to upend that country’s lending system. So, after a full nine months of gains this year, the stock markets are looking at the real

Implied VBK Analyst Target Price: $336
27 Sep, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Small-Cap Growth ETF (VBK), we found that the implied analyst target price for the ETF based upon its underlying holdings is $336.47 per unit.

Benzinga's Top Ratings Upgrades, Downgrades For September 22, 2021
22 Sep, 2021 FinancialContent

Upgrades Argus Research upgraded the previous rating for Simon Property Group Inc (NYSE:SPG) from Hold to Buy. In the ...

PMV Pharmaceuticals Appoints Tim Smith as Senior Vice President, Head of Corporate Development
09 Sep, 2021 FinancialContent
PMV Pharmaceuticals to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
02 Sep, 2021 FinancialContent
The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data
20 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Benzinga's Top Ratings Upgrades, Downgrades For August 19, 2021
19 Aug, 2021 FinancialContent

Upgrades According to DA Davidson, the prior rating for PaySign Inc (NASDAQ:PAYS) was changed from Neutral to Buy. In ...

PMV Pharmaceuticals Reports Second Quarter 2021 Financial Results and Corporate Highlights
13 Aug, 2021 FinancialContent
Benzinga's Top Ratings Upgrades, Downgrades For August 2, 2021
02 Aug, 2021 FinancialContent

Upgrades For Consolidated Communications Holdings Inc (NASDAQ:CNSL), Citigroup upgraded the previous rating of Sell to ...

Where Do Hedge Funds Stand On PMV Pharmaceuticals, Inc. (PMVP)?
19 Jul, 2021 Yahoo! Finance

Many prominent investors, including Warren Buffett, David Tepper and Stan Druckenmiller, have been cautious regarding the current bull market and missed out as the stock market reached another high in recent weeks. On the other hand, technology hedge funds weren’t timid and registered double digit market beating gains. Financials, energy and industrial stocks initially suffered […]

We're Hopeful That PMV Pharmaceuticals (NASDAQ:PMVP) Will Use Its Cash Wisely
23 Jun, 2021 Yahoo! Finance

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Analysts See 15% Upside For The Holdings of VBK
17 Jun, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Small-Cap Growth ETF (VBK), we found that the implied analyst target price for the ETF based upon its underlying holdings is $323.17 per unit.

PMV Pharmaceuticals Announces Participation at the Bank of America Securities 2021 Napa Biopharma Virtual Conference
09 Jun, 2021 FinancialContent
PMV Pharmaceuticals Announces Participation at the Goldman Sachs Annual Healthcare Conference
03 Jun, 2021 FinancialContent
PMV Pharmaceuticals Reports First Quarter 2021 Financial Results and Corporate Highlights
14 May, 2021 FinancialContent
Add Up The Pieces: XBI Could Be Worth $215
13 May, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR— S&P— Biotech ETF (XBI), we found that the implied analyst target price for the ETF based upon its underlying holdings is $214.98 per unit.

The Daily Biotech Pulse: Merck Reports Positive Keytruda Data In Breast Cancer, Curis, Evoke Slump On Earnings, Qiagen's Rapid COVID-19 Antibody Test OK'ed For Emergency Use
13 May, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Relative Strength Alert For PMV Pharmaceuticals
12 May, 2021 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

Stocks That Hit 52-Week Lows On Wednesday
12 May, 2021 FinancialContent

During the morning session on Wednesday, 21 stocks hit new 52-week lows. Significant Points: Brookfield ...

The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron
12 May, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

56 Biggest Movers From Yesterday
12 May, 2021 FinancialContent

Gainers Bridgford Foods Corporation (NASDAQ: BRID) shares surged 46.2% to close at $20.74 on Tuesday. Sequential Brands Group, ...

45 Stocks Moving In Tuesday's Mid-Day Session
11 May, 2021 FinancialContent

Gainers Sequential Brands Group, Inc. (NASDAQ: SQBG) surged 52.6% to $14.76 after dropping 11% on Monday. 3D Systems Corporation ...

PMV Pharmaceuticals Announces Participation at the Bank of America Healthcare Conference
05 May, 2021 FinancialContent
PMV Pharma Presents Late-Breaking Preclinical Data on Lead Product Candidate PC14586 at the American Association for Cancer Research Annual Meeting 2021
10 Apr, 2021 FinancialContent
Analysts Forecast 10% Gains Ahead For The Holdings of VBK
06 Apr, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Small-Cap Growth ETF (VBK), we found that the implied analyst target price for the ETF based upon its underlying holdings is $309.71 per unit.

PMV Pharmaceuticals, Inc (PMVP) is a NASDAQ Common Stock listed in , ,

970x250